Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists.

ABSTRACT:

Background

Despite the clinical efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for weight loss, real-world persistence remains substantially lower than seen in clinical trials. Since 2021, GLP-1RA shortages and changes in product availability have complicated access and persistence.

Objective

To describe by calendar year of initiation the 1-year treatment persistence and adherence trends among commercially insured members without diabetes newly initiating high-potency, weight loss-indicated GLP-1RA products, semaglutide (Wegovy) and tirzepatide (Zepbound).

Methods

This cohort study used Prime Therapeutics' integrated medical and pharmacy claims data from an average monthly membership of 17.9 million commercially insured individuals to identify member

SUBMITTER: Marshall LZ 

PROVIDER: S-EPMC12948759 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature